XML 30 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Our disaggregated revenues were as follows (in thousands):
Three Months Ended
 June 30,		Six Months Ended
June 30,
2023202220232022
Royalties$111,740 $85,340 $211,380 $154,945 
Product sales, net
  Sales of bulk rHuPH2027,133 25,057 49,202 41,505 
Sale of proprietary products32,293 14,687 60,254 20,379 
Sale of device partnered products14,463 6,556 25,227 6,556 
Total product sales, net$73,889 $46,300 $134,683 $68,440 
Revenues under collaborative agreements
  Upfront license and target nomination fees— 5,000 — 30,000 
  Event-based development and regulatory milestone and other fees33,000 15,000 33,000 15,000 
  Device licensing and development revenue2,409 725 4,118 1,259 
Total revenues under collaborative agreements$35,409 $20,725 $37,118 $46,259 
Total revenues$221,038 $152,365 $383,181 $269,644 
During the three months ended June 30, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $144.7 million. This amount represents royalties earned in the current period in addition to $33.0 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $2.7 million during the three months ended June 30, 2023 that had been included in deferred revenues in the condensed consolidated balance sheets as of December 31, 2022.
During the six months ended June 30, 2023, we recognized revenue related to licenses granted to partners in prior periods in the amount of $244.4 million. This amount represents royalties earned in the current period in addition to $33.0 million of variable consideration in the contracts where uncertainties were resolved and the development milestones are expected to be achieved or were achieved. We also recognized revenue of $3.1 million during the six months ended June 30, 2023 that had been included in deferred revenues in the condensed consolidated balance sheets as of December 31, 2022.
Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers, including partners, consisted of the following (in thousands):
June 30, 2023December 31, 2022
Accounts receivable, net$221,689 $186,970 
Other contract assets24,490 44,102 
Deferred revenues3,095 5,499 
As of June 30, 2023, the amounts included in the transaction price of our contracts with customers, including collaboration partners, and allocated to goods and services not yet provided were $127.5 million, of which $124.4 million relates to unfulfilled product purchase orders and $3.1 million has been collected and is reported as deferred revenues in the condensed consolidated balance sheets. The unfulfilled product purchase orders are estimated to be delivered by the end of 2024. Of the total deferred revenues of $3.1 million, $0.8 million is expected to be used by our customers within the next 12 months.
We recognized contract assets of $24.5 million as of June 30, 2023, which related to development milestones deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to the customer in accordance with the terms of the contract.